Kamada (NASDAQ:KMDA) Earns Buy Rating from Analysts at StockNews.com

Equities research analysts at StockNews.com initiated coverage on shares of Kamada (NASDAQ:KMDAGet Rating) in a research report issued on Monday. The brokerage set a “buy” rating on the biotechnology company’s stock.

Kamada Stock Performance

NASDAQ:KMDA opened at $4.53 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.39 and a quick ratio of 1.09. The firm has a 50-day moving average of $4.53 and a two-hundred day moving average of $4.69. The stock has a market cap of $202.94 million, a P/E ratio of -17.42 and a beta of 0.94. Kamada has a 1-year low of $4.11 and a 1-year high of $6.96.

Hedge Funds Weigh In On Kamada

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Phoenix Holdings Ltd. boosted its position in Kamada by 12.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 2,059,911 shares of the biotechnology company’s stock valued at $9,105,000 after buying an additional 227,819 shares during the last quarter. Altshuler Shaham Ltd raised its stake in shares of Kamada by 7.2% in the 3rd quarter. Altshuler Shaham Ltd now owns 919,697 shares of the biotechnology company’s stock valued at $4,630,000 after purchasing an additional 61,703 shares in the last quarter. Acadian Asset Management LLC raised its stake in shares of Kamada by 7.2% in the 1st quarter. Acadian Asset Management LLC now owns 877,798 shares of the biotechnology company’s stock valued at $4,886,000 after purchasing an additional 58,866 shares in the last quarter. Vanguard Group Inc. raised its stake in shares of Kamada by 7.3% in the 3rd quarter. Vanguard Group Inc. now owns 864,789 shares of the biotechnology company’s stock valued at $3,900,000 after purchasing an additional 58,705 shares in the last quarter. Finally, Dimensional Fund Advisors LP raised its stake in shares of Kamada by 32.5% in the 1st quarter. Dimensional Fund Advisors LP now owns 68,889 shares of the biotechnology company’s stock valued at $380,000 after purchasing an additional 16,886 shares in the last quarter.

Kamada Company Profile

(Get Rating)

Kamada Ltd. provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers KAMRAB/KEDRAB for prophylaxis of rabies disease; CYTOGAM for prophylaxis of cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplant; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD.

Featured Articles

Receive News & Ratings for Kamada Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kamada and related companies with MarketBeat.com's FREE daily email newsletter.